Adma Biologics Inc
Research Adma Biologics Inc (ADMA) on Bullrun: valuation model: 47.0% undervalued, market cap USD 2.19B, P/E 13.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADMA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal47.0% undervalued
- Market capUSD 2.19B
- P/E13.8
- Financial periodQ2 2026
- RevenueUSD 124.40M
- Net incomeUSD 37.82M
- Free cash flowUSD 27.28M
- Gross margin69.4%
Valuation Snapshot
Bullrun's latest valuation model marks Adma Biologics Inc as 47.0% undervalued; latest market cap is USD 2.19B; P/E is 13.8.
Peer valuation comparison
Latest P/E is 13.8x versus a Healthcare sector median of 24.46x (43.6% below).
Latest P/E is 13.8x versus a United States median of 24.87x (44.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 510.17M | USD 146.93M | USD 27.82M | 57.4% | 0.6 | USD 87.63M | USD 72.14M | USD 477.32M |
| FY2024 | USD 426.45M | USD 197.70M | USD 110.45M | 51.5% | 0.81 | USD 103.15M | USD 72.34M | USD 349.02M |
| FY2023 | USD 258.22M | -USD 28.20M | USD 4.03M | 34.4% | -0.13 | USD 51.35M | USD 141.42M | USD 135.21M |
| FY2022 | USD 154.08M | -USD 65.90M | -USD 73.42M | 22.9% | -0.33 | USD 86.52M | USD 151.26M | USD 151.97M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.19B | 13.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.34B | 30.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.06B | 21.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.02B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 857.10M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 276.10M | n/a | n/a | n/a |
About Adma Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Adma Biologics Inc overvalued or undervalued?
Bullrun's valuation model currently marks Adma Biologics Inc as 47.0% undervalued.
What is Adma Biologics Inc's market cap?
Adma Biologics Inc's market capitalization is USD 2.19B.
What is Adma Biologics Inc's P/E ratio?
Adma Biologics Inc's price-to-earnings (P/E) ratio is 13.8.
What does Adma Biologics Inc do?
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.